ロード中...
Cachectic Cancer Patients: Immune to Check-point Inhibitor Therapy?
Immune check-point inhibition is dramatically improving patient outcomes in diverse cancers, many of which responded poorly to traditional cytotoxic agents. Drivers of heterogeneous response to immune check-point therapy are poorly characterized. Cachectic cancer patients exhibit elevated pembrolizu...
保存先:
| 出版年: | Clin Cancer Res |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6279566/ https://ncbi.nlm.nih.gov/pubmed/30018117 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-1847 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|